Prostate cancer is one of the most common male-related cancers, and understanding the underlying mechanisms is crucial for developing new treatment strategies and avoiding resistance development.
Nuclidium AG is poised to circumvent the complex production and supply issues that have held back access to radiopharmaceuticals after closing a CHF79 million (US$99.3 million) series B, to advance the clinical development of its copper isotopes and extend the global manufacturing network.
Innocare Pharma Ltd. has obtained IND approval from China’s National Medical Products Administration (NMPA) to initiate a clinical trial of the B7-H3 targeted antibody-drug conjugate.
Vitsgen Therapeutics Inc. recently provided details on the preclinical characterization of a new prostate-specific membrane antigen (PSMA)-targeted radiotheranostic agent, [177Lu]PSMA-VG-01, for the treatment of metastatic castration-resistant prostate cancer.
Actinium Pharmaceuticals Inc. recently presented data on ATNM-400, a new antibody radioconjugate that uses actinium-225 (Ac-225) to target a non-prostate-specific member antigen (PSMA) protein that is frequently overexpressed in several tumor types, including prostate cancer.
At the 2025 Annual Congress of the European Association for Cancer Research (EACR), researchers from Cardiff University and collaborators presented their research on the role of BCL3 in tumor progression and the therapeutic potential of TNAT-101.
Archeus Technologies Inc. has obtained IND clearance from the FDA for ART-101, a novel receptor-based targeting small molecule for the imaging and treatment of prostate cancer.
Among the presentations included in the Top Abstracts category at the recently inaugurated Annual Congress of the European Association for Cancer Research (EACR) in Lisbon, it is worth highlighting two that respectively addressed the role of cytokines and lipid-sensing receptors as key modulators of the tumor microenvironment, a central theme in current cancer research.
Philochem AG’s ligand-targeting approach drew to the table Bristol Myers Squibb Co. in a potential $1.35 billion agreement granting BMS subsidiary Rayzebio Inc. exclusive worldwide rights to OncoACP3, a diagnostic and therapeutic candidate targeting prostate cancer.
Epimab Biotherapeutics Inc. licensed out a development-ready KLK2/CD3 bispecific T-cell engager (TCE) for advanced prostate cancer to Juri Biosciences Inc. through a potential $210 million deal.
